539 related articles for article (PubMed ID: 9296275)
1. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Aoki T; Nishimura H; Nakagawa S; Kojima J; Suzuki H; Tamaki T; Wada Y; Yokoo N; Sato F; Kimata H; Kitahara M; Toyoda K; Sakashita M; Saito Y
Arzneimittelforschung; 1997 Aug; 47(8):904-9. PubMed ID: 9296275
[TBL] [Abstract][Full Text] [Related]
2. Hypolipidemic effect of NK-104 and other 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in guinea pigs.
Suzuki H; Yamazaki H; Aoki T; Tamaki T; Sato F; Kitahara M; Saito Y
Arzneimittelforschung; 2001 Jan; 51(1):38-45. PubMed ID: 11215324
[TBL] [Abstract][Full Text] [Related]
3. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
[TBL] [Abstract][Full Text] [Related]
4. Cholesterol content of the rat lens is lowered by administration of simvastatin, but not by pravastatin.
De Vries AC; Vermeer MA; Bredman JJ; Bär PR; Cohen LH
Exp Eye Res; 1993 Apr; 56(4):393-9. PubMed ID: 8500554
[TBL] [Abstract][Full Text] [Related]
5. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.
Amin D; Rutledge RZ; Needle SN; Galczenski HF; Neuenschwander K; Scotese AC; Maguire MP; Bush RC; Hele DJ; Bilder GE; Perrone MH
J Pharmacol Exp Ther; 1997 May; 281(2):746-52. PubMed ID: 9152381
[TBL] [Abstract][Full Text] [Related]
6. Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers.
Pierno S; De Luca A; Tricarico D; Roselli A; Natuzzi F; Ferrannini E; Laico M; Camerino DC
J Pharmacol Exp Ther; 1995 Dec; 275(3):1490-6. PubMed ID: 8531120
[TBL] [Abstract][Full Text] [Related]
7. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro.
Kurakata S; Kada M; Shimada Y; Komai T; Nomoto K
Immunopharmacology; 1996 Aug; 34(1):51-61. PubMed ID: 8880225
[TBL] [Abstract][Full Text] [Related]
8. Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia.
Aoki T; Yamazaki H; Suzuki H; Tamaki T; Sato F; Kitahara M; Saito Y
Arzneimittelforschung; 2001; 51(3):197-203. PubMed ID: 11304935
[TBL] [Abstract][Full Text] [Related]
9. [Effect of the inhibitors of 3-hydroxy-3-methylglutaryl coenzyme-A reductase, pravastatin and simvastatin, on colony formation by hematopoietic progenitor cells].
Kunitama M; Komatsu N; Miura Y
Rinsho Ketsueki; 1996 Nov; 37(11):1314-7. PubMed ID: 8960668
[TBL] [Abstract][Full Text] [Related]
10. Lipid-lowering and antiatherosclerotic effect of NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in Watanabe heritable hyperlipidemic rabbits.
Suzuki H; Yamazaki H; Aoki T; Kojima J; Tamaki T; Sato F; Kitahara M; Saito Y
Arzneimittelforschung; 2000 Nov; 50(11):995-1003. PubMed ID: 11187394
[TBL] [Abstract][Full Text] [Related]
11. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens.
Mosley ST; Kalinowski SS; Schafer BL; Tanaka RD
J Lipid Res; 1989 Sep; 30(9):1411-20. PubMed ID: 2513368
[TBL] [Abstract][Full Text] [Related]
12. Tissue-selective inhibition of sterol synthesis in mice by pravastatin sodium after a single or repeated oral administrations.
Koga T; Kikuchi T; Miyazaki A; Koike H
Lipids; 1995 Aug; 30(8):775-9. PubMed ID: 7475995
[TBL] [Abstract][Full Text] [Related]
13. The effect of pravastatin on hepatic 3-hydroxy-3-methylglutaryl CoA reductase obtained from poloxamer 407-induced hyperlipidemic rats.
Johnston TP; Palmer WK
Pharmacotherapy; 1997; 17(2):342-7. PubMed ID: 9085326
[TBL] [Abstract][Full Text] [Related]
14. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug.
Vickers S; Duncan CA; Chen IW; Rosegay A; Duggan DE
Drug Metab Dispos; 1990; 18(2):138-45. PubMed ID: 1971563
[TBL] [Abstract][Full Text] [Related]
15. Regulation of early cholesterol biosynthesis in rat liver: effects of sterols, bile acids, lovastatin, and BM 15.766 on 3-hydroxy-3-methylglutaryl coenzyme A synthase and acetoacetyl coenzyme A thiolase activities.
Honda A; Salen G; Nguyen LB; Xu G; Tint GS; Batta AK; Shefer S
Hepatology; 1998 Jan; 27(1):154-9. PubMed ID: 9425931
[TBL] [Abstract][Full Text] [Related]
16. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
[TBL] [Abstract][Full Text] [Related]
17. Effects of simvastatin, a cholesterol synthesis inhibitor, on phosphatidylcholine synthesis in HepG2 cells.
Yanagita T; Yamamoto K; Ishida S; Sonda K; Morito F; Saku K; Sakai T
Clin Ther; 1994; 16(2):200-8. PubMed ID: 8062316
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of rat brain prostaglandin D synthase by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Islam F; Watanabe Y; Hayaishi O
Biochem Int; 1990 Nov; 22(4):601-5. PubMed ID: 2127671
[TBL] [Abstract][Full Text] [Related]
19. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier.
Tsuji A; Saheki A; Tamai I; Terasaki T
J Pharmacol Exp Ther; 1993 Dec; 267(3):1085-90. PubMed ID: 8263769
[TBL] [Abstract][Full Text] [Related]
20. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin.
Thelen KM; Rentsch KM; Gutteck U; Heverin M; Olin M; Andersson U; von Eckardstein A; Björkhem I; Lütjohann D
J Pharmacol Exp Ther; 2006 Mar; 316(3):1146-52. PubMed ID: 16282522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
